News

The study included 112 men with prostate cancer with an average age of 71. After an average of two years of androgen deprivation therapy for prostate cancer, only

AZX100 is currently being investigated for indications such as the treatment of vasospasm associated with subarachnoid hemorrhage, the prevention of keloid scarring, and the treatment of asthma. Preclinical

Algeta, headquartered in Norway, is conducting the trial as part of its phase II clinical program for Alpharadin, a novel radiopharmaceutical based on the alpha particle emitter radium-223,

The tablets are a generic version of the active ingredient found in Luvox which was formerly marketed by Solvay Pharmaceuticals. However, the Luvox brand is no longer available

Arisaph received a significant upfront payment upon execution and will receive development milestone payments and a royalty on sales. Additional financial terms were not disclosed. “We are extremely

The patients enrolled in the trial have been randomized to receive placebo or one of two flexible dose regimens of MN-305 at 25 clinical sites in the US.

The product is specifically indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and prevention of postoperative

The combination of the companies forms a new biotechnology company under the name of Ambrilia Biopharma that will develop therapeutics in the fields of oncology and infectious diseases.

Under the agreement, Baxter will complete delivery of the stockpile to the NHS in 2006. “We are proud to provide the necessary technology, manufacturing capability and other resources